<p>A. Binding activity of Y-142 and Y-073 toward sHB-EGF. Anti-HB-EGF antibody was incubated at various concentrations in an sHB-EGF-coated or a BSA-coated plate. Antibody binding was detected with an HRP-labeled anti-mouse IgG antibody. Y-142 binding to BSA, white square; Y-073 binding to BSA, white circle; Y-142 binding to sHB-EGF, black square; Y-073 binding to sHB-EGF, black circle. The data points represent the mean ± standard deviation (SD) of values acquired in duplicate. B. Neutralizing activity of Y-142 and Y-073 against sHB-EGF-induced EGFR phosphorylation. Anti-HB-EGF antibody was incubated at the indicated concentrations in the presence of 10 nM sHB-EGF with NUGC-3 cells for 15 minutes at 37°C. Cell lysates were incubated on an ...
<p><i>A</i>–<i>E.</i> Serum-starved A431 cells were treated for five minutes with different concentr...
<p>A) Equilibrium binding of A5 and F4 IgGs to purified ERBB3 extracellular domains was quantified i...
The field of targeted cancer therapy has progressed in recent years with the approval of new oncolog...
<p>(A) The binding activity of Y-142 to EGFR ligands by ELISA. The various concentrations of Y-142 w...
<p>(A) Inhibitory activity of Y-142 to sHB-EGF binding to EGFR. EGFR-hFc was incubated in an anti-hu...
<p>A. Binding of anti-HB-EGF antibody to proHB-EGF. The cells were incubated with anti-HB-EGF antibo...
<p>(A) and (B) Neutralizing activities of Y-142 against (A) sHB-EGF-induced SK-OV-3 cell proliferati...
<p>The binding of Y-142 to a linear or conformational epitope was tested using Western blot. sHB-EGF...
PURPOSE: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epid...
<p>proHB-EGF juxtacrine activity was measured using Y-142. NUGC-3 cells in a spheroid culture plate ...
<div><p>Purpose</p><p>Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a membe...
<p>Epitope mapping of Y-142 was performed using alanine scanning. Each mutant proHB-EGF expression p...
<p>Dual-curve KinExA equilibrium titration of sHB-EGF binding to Y-142. K<sub>D</sub>-controlled dat...
<p>(A) EGFR binding assay. Each antibody was incubated with EGFR-overexpressed A431cells and then bi...
<p>Spheroid formation and cell proliferation by proHB-EGF function were assessed under Y-142 treatme...
<p><i>A</i>–<i>E.</i> Serum-starved A431 cells were treated for five minutes with different concentr...
<p>A) Equilibrium binding of A5 and F4 IgGs to purified ERBB3 extracellular domains was quantified i...
The field of targeted cancer therapy has progressed in recent years with the approval of new oncolog...
<p>(A) The binding activity of Y-142 to EGFR ligands by ELISA. The various concentrations of Y-142 w...
<p>(A) Inhibitory activity of Y-142 to sHB-EGF binding to EGFR. EGFR-hFc was incubated in an anti-hu...
<p>A. Binding of anti-HB-EGF antibody to proHB-EGF. The cells were incubated with anti-HB-EGF antibo...
<p>(A) and (B) Neutralizing activities of Y-142 against (A) sHB-EGF-induced SK-OV-3 cell proliferati...
<p>The binding of Y-142 to a linear or conformational epitope was tested using Western blot. sHB-EGF...
PURPOSE: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epid...
<p>proHB-EGF juxtacrine activity was measured using Y-142. NUGC-3 cells in a spheroid culture plate ...
<div><p>Purpose</p><p>Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a membe...
<p>Epitope mapping of Y-142 was performed using alanine scanning. Each mutant proHB-EGF expression p...
<p>Dual-curve KinExA equilibrium titration of sHB-EGF binding to Y-142. K<sub>D</sub>-controlled dat...
<p>(A) EGFR binding assay. Each antibody was incubated with EGFR-overexpressed A431cells and then bi...
<p>Spheroid formation and cell proliferation by proHB-EGF function were assessed under Y-142 treatme...
<p><i>A</i>–<i>E.</i> Serum-starved A431 cells were treated for five minutes with different concentr...
<p>A) Equilibrium binding of A5 and F4 IgGs to purified ERBB3 extracellular domains was quantified i...
The field of targeted cancer therapy has progressed in recent years with the approval of new oncolog...